REGISTER LOG IN CORPORATE About NanoString Careers News Events Contact Us Company Investors Life Sciences Prosigna™ NanoString® Technologies nCounter® Analysis System Pathway-based Translational Research Oncology Molecular Dx NanoString® Technologies develops innovative products that unlock valuable and clinically actionable genomic information from small amounts of tissue. We are committed to providing tools that enable scientists and clinicians to translate today’s leading research into clinically actionable tests that improve patient care. The nCounter® Analysis System and related consumables have been adopted by academic, government and commercial research laboratories worldwide. NanoString Technologies (or: “The Company”) obtained CE Mark in September 2012, and FDA 510(k) clearance in September 2013, for the Prosigna™ Breast Cancer Assay representing our initial offering in the molecular diagnostics market. 1 page 2 page 3 page 4 page 5 page Link to Life Sciences Link to Prosigna.com NANOSTRING NEWS IN THE NEWS Prosigna™ Breast Cancer Assay Named TOP 10 Innovations of 2013 by The Scientist READ MORE FEATURED VIDEO nCounter PanCancer Pathways Panel VIEW VIDEO Webinar Download This webinar is sponsored by CHI Featuring Dr. Mao and Jay Gerlach DOWNLOAD Featured Publications » VIEW ALL Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Ullal A.V. et al., January 15, 2014 Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin embedded tissue. Scott D.W. et al., January 7, 2014 Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples Northcott PA, et al., November 6, 2011 Upcoming Events » VIEW ALL NanoString Technology Awareness Seminar at University of Wisconsin September 29, 2014 NanoString Technology Awareness Seminar at CCHMC October 1, 2014 NanoString Technology Awareness Seminar at UAB October 6, 2014 Recent Publications » VIEW ALL Mycobacterium tuberculosis Decreases Human Macrophage IFN-γ Responsiveness through miR-132 and miR-26a. Ni B. et al., September 24, 2014 CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth. Mathsyaraja H. et al., September 22, 2014 Wnt pathway in atypical teratoid rhabdoid tumors. Chakravadhanula M. et al., September 21, 2014 Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Lee S.E. et al., September 19, 2014 Dendritic cell-bound IgE functions to restrain allergic inflammation at mucosal sites. Platzer B. et al., September 17, 2014 Press Releases » VIEW ALL September 9, 2014 NanoString Introduces Novel Gene Expression Panel for Immuno-Oncology Research August 27, 2014 NanoString Announces Unexpected Death of Chief Medical Officer, J. Wayne Cowens, MD August 21, 2014 NanoString Technologies to Present at Upcoming Investor Conferences In the News » VIEW ALL September 10, 2013 NCI Scientists Identify Targets for Melanoma Immunotherapy September 10, 2013 In BD Deal, NanoString Looks to Broaden Appeal to Single-Cell Genomics Researchers CORPORATE Company Overview Management Team Press / Media Request Information Location / Contact Distributors - LS Careers Legal Privacy Policy Cookies Policy LIFE SCIENCES Life Sciences Home nCounter® Technology nCounter® Dx System nCounter® Products nCounter Elements™ GPRs Applications Overview nCounter Publications Request Information Order Information Contact Support nDesign™ Gateway PROSIGNA™ Prosigna Home Intrinsic Subtypes Risk of Recurrence Clinical Studies Technology Workflow Order Information Contact Us Contact Us NanoString Technologies, Inc. 530 Fairview Ave N Suite 2000 Seattle, WA 98109 Tel: 1 888 358 6266 Fax: 1 206 378 6288 E-mail: info@nanostring.com SUBSCRIBE TO NEWSLETTER Follow Us Follow @nanostringtech © 2014 NanoString® Technologies, Inc. All rights reserved. Corporate Overview Investors Life Sciences Prosigna™ Legal Privacy Policy Cookies Policy 1 888 358 6266